Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 2.3× earnings vs its 21.9× historical median P/E.
Fair value ≈ $0.24 · price $0.03 today
Undervalued · 90% below
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$RAFA Conversation
O8OBP9m-_x96.jpg
Rafarma Pharmaceuticals, USA
@RAFArma_Pharma
Rafarma is pleased to announce a multi-million dollar agreement for the development of isotopes and nuclear medicine between its Korean subsidiary HWARIM PHARMTECH and Korean giant Woods Medical Care, Moscow-Busan, November 2025
#rafarma
Image.jpeg
Image.jpeg
$BINI $GME $HOG $RAFA You gotta admit your bit of a stalker eh? I’m gonna admit it, I shorted it and made a quarter milli, and now I’ll pump it to several dollars. Sitting on 1.7 mil shares now as of this week. This will be my biggest gains ever.
$RAFA They just filed their management certification and attorney letter for end of 2024 with OTCMarkets. Stock is starting to respond. https://www.otcmarkets.com/stock/RAFA/disclosure
